Nontuberculous Mycobacteria clinical trials at UCSF
2 research studies open to eligible people
Nontuberculous mycobacteria are bacteria that can lead to lung disease. UCSF is currently comparing two-drug versus three-drug treatments for one of these diseases. Another trial at UCSF is testing a new inhaled medicine for these infections.
Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
open to eligible people ages 18 years and up
NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.
San Francisco, California and other locations
ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
open to eligible people ages 18 years and up
The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared to the ELC (empty liposome control) + background regimen on participant-reported respiratory symptoms at Month 13.
San Francisco, California and other locations
Our lead scientists for Nontuberculous Mycobacteria research studies include Payam Nahid, MD, MPH.
Last updated: